These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 18847557

  • 21. HPV prophylactic vaccination: The first years and what to expect from now.
    Villa LL.
    Cancer Lett; 2011 Jun 28; 305(2):106-12. PubMed ID: 21190794
    [Abstract] [Full Text] [Related]

  • 22. Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine.
    Godi A, Bissett SL, Miller E, Beddows S.
    PLoS One; 2015 Jun 28; 10(10):e0140926. PubMed ID: 26495976
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.
    Smith JF, Brownlow M, Brown M, Kowalski R, Esser MT, Ruiz W, Barr E, Brown DR, Bryan JT.
    Hum Vaccin; 2007 Jun 28; 3(4):109-15. PubMed ID: 17611417
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
    Muñoz N, Manalastas R, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A.
    Lancet; 2009 Jun 06; 373(9679):1949-57. PubMed ID: 19493565
    [Abstract] [Full Text] [Related]

  • 31. Measuring serum antibody to human papillomavirus following infection or vaccination.
    Frazer IH.
    Gynecol Oncol; 2010 Jun 06; 118(1 Suppl):S8-11. PubMed ID: 20494221
    [Abstract] [Full Text] [Related]

  • 32. Comparison of the immunogenicity of Cervarix® and Gardasil® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults.
    Toft L, Tolstrup M, Müller M, Sehr P, Bonde J, Storgaard M, Østergaard L, Søgaard OS.
    Hum Vaccin Immunother; 2014 Jun 06; 10(5):1147-54. PubMed ID: 24553190
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine.
    Bryan JT, Buckland B, Hammond J, Jansen KU.
    Curr Opin Chem Biol; 2016 Jun 06; 32():34-47. PubMed ID: 26994695
    [Abstract] [Full Text] [Related]

  • 35. Prophylactic immunization with human papillomavirus vaccines induces oral immunity in mice.
    Ahn J, Peng S, Hung CF, Roden RBS, Best SR.
    Laryngoscope; 2018 Jan 06; 128(1):E16-E20. PubMed ID: 28868617
    [Abstract] [Full Text] [Related]

  • 36. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
    Van Damme P, Leroux-Roels G, Simon P, Foidart JM, Donders G, Hoppenbrouwers K, Levin M, Tibaldi F, Poncelet S, Moris P, Dessy F, Giannini SL, Descamps D, Dubin G.
    Vaccine; 2014 Jun 17; 32(29):3694-705. PubMed ID: 24674663
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Human papillomavirus vaccine and cervical cancer prevention: practice and policy implications for pharmacists.
    McIntosh J, Sturpe DA, Khanna N.
    J Am Pharm Assoc (2003); 2008 Jun 17; 48(1):e1-13; quiz e14-7. PubMed ID: 18192123
    [Abstract] [Full Text] [Related]

  • 40. Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus.
    Herrin DM, Coates EE, Costner PJ, Kemp TJ, Nason MC, Saharia KK, Pan Y, Sarwar UN, Holman L, Yamshchikov G, Koup RA, Pang YY, Seder RA, Schiller JT, Graham BS, Pinto LA, Ledgerwood JE.
    Hum Vaccin Immunother; 2014 Jun 17; 10(12):3446-54. PubMed ID: 25483691
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.